Sector News

Why didn’t J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

April 7, 2015
Life sciences
Why didn’t Johnson & Johnson buy Pharmacyclics? Good question–and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.
 
Recall that J&J is Pharmacyclics’ partner on the blood cancer drug Imbruvica, a fast-growing therapy in a hot field. It’s a partnership that J&J struck years ago, at a cost of some $975 million, plus a split of eventual profits. Last month, AbbVie agreed to buy Pharmacyclics–including its share of Imbruvica and some pipeline meds–for $21 billion.
 
The price stunned many analysts at the time, and Gorsky used the familiar words “thoughtful” and “disciplined” in answering the WSJ’s question. The vast majority of J&J’s acquisitions over the past 10 years–more than 100 in all–have been under $1 billion, the CEO said.
 
“Most of our investments tend to be early-on, smaller, midsize,” Gorsky told the Journal. “Occasionally we’ll go big as we did when we went after Synthes not too long ago.
 
“But in the pharma space, identifying another Zytiga, identifying the next Imbruvica is something that we’re very interested in.”
 
In other words, buy low, sell high. In biopharma, that means risk–there’s no guarantee, of course, that pipeline drugs will actually pay off as hoped–but it also means less of a write down if expectations aren’t met down the road. And J&J’s team has a strong track record of picking winners. Zytiga, for instance, is the prostate cancer pill that J&J acquired with Cougar Biotech in 2009 for $1 billion. Approved in 2011, Zytiga brought in $2.25 billion for the company last year, partly in thanks to an aggressive development program that quickly put Zytiga on the front lines of prostate cancer treatment.
 
J&J was rumored to be among the final bidders for Pharmacyclics. According to a recent securities filing, AbbVie outbid the other potential buyers by $11.25 per share in the last round, or about $1 billion. But one of those last-round bids came from a so-called Party A, the first company approached about a potential deal, the one said to be J&J.
 
Party A’s first offer was $225 per share in cash and stock, not much higher than its trading price at the time, what with rumors circulating about a merger. AbbVie’s offering in that round was $250 per share in cash and stock, with another bidder–Party B–in the middle at $240 per share. Party A’s second bid was $250 per share–but it was all cash, a structure Pharmacyclics had specifically said it didn’t want. All but guaranteed to be a nonstarter. Party B, also $250 per share, but in with stock as 42.5% of the deal. AbbVie’s? Cash and stock worth $261.25 per share.
 
By Tracy Staton
 

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach